{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:56:46Z","timestamp":1759694206954},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Behav Brain Funct"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In contrast to olanzapine, ziprasidone has been reported to cause minimal or no weight gain. This study aimed to compare the effects of ziprasidone and olanzapine on weight, body composition, appetite, resting energy expenditure, substrate oxidation, and metabolic parameters in adults with schizophrenia or other psychotic disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty adults with schizophrenia or other psychotic disorders were randomized 1:1 to ziprasidone 20\u2013160\u00a0mg\/day or olanzapine 5\u201320\u00a0mg\/day for 12\u00a0weeks. The mean doses during the 12-week study period were 109(range: 65\u2013140) mg\/day for ziprasidone and 11.6(range: 8.2\u201315.5) mg\/day for olanzapine. Body weight, appetite, body composition, resting energy expenditure, and metabolic parameters were measured before and after drug treatment. Outcome measurements before and after medication were compared, and ziprasidone- and olanzapine-treated patients were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 12\u00a0weeks, olanzapine-treated patients showed significant weight gain, particularly fat gain, with increased low density lipoprotein-cholesterol and decreased high density lipoprotein-cholesterol concentrations. In contrast, ziprasidone-treated patients showed no significant weight gain with increased high density lipoprotein-cholesterol concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ziprasidone was associated with a lower propensity for weight gain and central fat deposition than olanzapine. Studies in larger patient samples are required to confirm these results.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1744-9081-9-27","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T08:14:16Z","timestamp":1374221656000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study"],"prefix":"10.1186","volume":"9","author":[{"given":"Subin","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Kyoung","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Pyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,19]]},"reference":[{"issue":"Suppl 7","key":"460_CR1","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001, 62 (Suppl 7): 22-31.","journal-title":"J Clin Psychiatry"},{"key":"460_CR2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999, 156: 1686-1696.","journal-title":"Am J Psychiatry"},{"key":"460_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.psychres.2010.04.050","volume":"185","author":"E Lee","year":"2011","unstructured":"Lee E, Chow LY, Leung CM: Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry Res. 2011, 185: 456-458. 10.1016\/j.psychres.2010.04.050.","journal-title":"Psychiatry Res"},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","volume":"41","author":"G Ratzoni","year":"2002","unstructured":"Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002, 41: 337-343. 10.1097\/00004583-200203000-00014.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"460_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2007.05.036","volume":"95","author":"S Saddichha","year":"2007","unstructured":"Saddichha S, Ameen S, Akhtar S: Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res. 2007, 95: 247-10.1016\/j.schres.2007.05.036.","journal-title":"Schizophr Res"},{"key":"460_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/ajp.154.4.457","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997, 154: 457-465.","journal-title":"Am J Psychiatry"},{"key":"460_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4088\/JCP.v65n0417","volume":"65","author":"N Almeras","year":"2004","unstructured":"Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH: Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004, 65: 557-564. 10.4088\/JCP.v65n0417.","journal-title":"J Clin Psychiatry"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4088\/JCP.v59n0604","volume":"59","author":"S Hagg","year":"1998","unstructured":"Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R: Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998, 59: 294-299. 10.4088\/JCP.v59n0604.","journal-title":"J Clin Psychiatry"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00002018-200225150-00005","volume":"25","author":"K Hedenmalm","year":"2002","unstructured":"Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O: Glucose intolerance with atypical antipsychotics. Drug Saf. 2002, 25: 1107-1116. 10.2165\/00002018-200225150-00005.","journal-title":"Drug Saf"},{"key":"460_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.schres.2004.03.024","volume":"71","author":"H Jin","year":"2004","unstructured":"Jin H, Meyer JM, Jeste DV: Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004, 71: 195-212. 10.1016\/j.schres.2004.03.024.","journal-title":"Schizophr Res"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","volume":"64","author":"K Melkersson","year":"2004","unstructured":"Melkersson K, Dahl ML: Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004, 64: 701-723. 10.2165\/00003495-200464070-00003.","journal-title":"Drugs"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","volume":"17","author":"M Arato","year":"2002","unstructured":"Arato M, O'Connor R, Meltzer HY: A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002, 17: 207-215. 10.1097\/00004850-200209000-00001.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 19","key":"460_CR13","first-page":"40","volume":"64","author":"DG Daniel","year":"2003","unstructured":"Daniel DG: Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry. 2003, 64 (Suppl 19): 40-49.","journal-title":"J Clin Psychiatry"},{"key":"460_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4088\/JCP.v62n0507","volume":"62","author":"SJ Kingsbury","year":"2001","unstructured":"Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM: The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001, 62: 347-349. 10.4088\/JCP.v62n0507.","journal-title":"J Clin Psychiatry"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eurpsy.2006.06.004","volume":"22","author":"D Kudla","year":"2007","unstructured":"Kudla D, Lambert M, Domin S, Kasper S, Naber D: Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry. 2007, 22: 195-202. 10.1016\/j.eurpsy.2006.06.004.","journal-title":"Eur Psychiatry"},{"key":"460_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/10673220701679838","volume":"15","author":"TC Manschreck","year":"2007","unstructured":"Manschreck TC, Boshes RA: The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007, 15: 245-258. 10.1080\/10673220701679838.","journal-title":"Harv Rev Psychiatry"},{"key":"460_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.pnpbp.2007.06.008","volume":"31","author":"Y Ratner","year":"2007","unstructured":"Ratner Y, Gibel A, Yorkov V, Ritsner MS: Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 1401-1409. 10.1016\/j.pnpbp.2007.06.008.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00004850-200503000-00008","volume":"20","author":"RR Brown","year":"2005","unstructured":"Brown RR, Estoup MW: Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol. 2005, 20: 105-112. 10.1097\/00004850-200503000-00008.","journal-title":"Int Clin Psychopharmacol"},{"key":"460_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","volume":"33","author":"SW Kim","year":"2010","unstructured":"Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS: Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010, 33: 121-125. 10.1097\/WNF.0b013e3181d52b85.","journal-title":"Clin Neuropharmacol"},{"key":"460_CR20","first-page":"CD006627","volume-title":"Cochrane Database Syst Rev","author":"K Komossa","year":"2009","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S: Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009, CD006627-"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2174\/1389450043490514","volume":"5","author":"T Baptista","year":"2004","unstructured":"Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004, 5: 279-299. 10.2174\/1389450043490514.","journal-title":"Curr Drug Targets"},{"key":"460_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00213-007-0833-9","volume":"194","author":"MJ Fell","year":"2007","unstructured":"Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC: The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl). 2007, 194: 221-231. 10.1007\/s00213-007-0833-9.","journal-title":"Psychopharmacology (Berl)"},{"key":"460_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.bbr.2010.08.046","volume":"216","author":"M Shobo","year":"2011","unstructured":"Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y: Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res. 2011, 216: 561-568. 10.1016\/j.bbr.2010.08.046.","journal-title":"Behav Brain Res"},{"key":"460_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1590\/S1807-59322010000900012","volume":"65","author":"M von Wilmsdorff","year":"2010","unstructured":"von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A, Gaebel W: The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics (Sao Paulo). 2010, 65: 885-894. 10.1590\/S1807-59322010000900012.","journal-title":"Clinics (Sao Paulo)"},{"key":"460_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.metabol.2011.10.011","volume":"61","author":"S Park","year":"2012","unstructured":"Park S, Kim MS, Namkoong C, Park MH, Hong JP: The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012, 61: 787-793. 10.1016\/j.metabol.2011.10.011.","journal-title":"Metabolism"},{"key":"460_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","volume":"159","author":"D Gothelf","year":"2002","unstructured":"Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 2002, 159: 1055-1057. 10.1176\/appi.ajp.159.6.1055.","journal-title":"Am J Psychiatry"},{"key":"460_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","volume":"162","author":"KA Graham","year":"2005","unstructured":"Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB: Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005, 162: 118-123. 10.1176\/appi.ajp.162.1.118.","journal-title":"Am J Psychiatry"},{"key":"460_CR28","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","volume":"68","author":"R Perez-Iglesias","year":"2007","unstructured":"Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL: A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007, 68: 1733-1740. 10.4088\/JCP.v68n1113.","journal-title":"J Clin Psychiatry"},{"key":"460_CR29","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/oby.2010.6","volume":"18","author":"RJ Fountaine","year":"2010","unstructured":"Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA: Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010, 18: 1646-1651. 10.1038\/oby.2010.6.","journal-title":"Obesity (Silver Spring)"},{"key":"460_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-2002-31521","volume":"35","author":"M Virkkunen","year":"2002","unstructured":"Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A: Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry. 2002, 35: 124-126. 10.1055\/s-2002-31521.","journal-title":"Pharmacopsychiatry"},{"key":"460_CR31","first-page":"362","volume":"39","author":"OS Hahn","year":"2000","unstructured":"Hahn OS, Ahn JH, Song SH, Cho MJ, Kim JK, Bae JN: Development of Korean version of structured clinical interview schedule for DSM-IV axis I disorder : interrater reliability. Journal of the Korean Neuropsychiatric Association. 2000, 39: 362-372.","journal-title":"Journal of the Korean Neuropsychiatric Association"},{"key":"460_CR32","first-page":"1090","volume":"40","author":"J-S Yi","year":"2002","unstructured":"Yi J-S, Ahn YM, Shin H-K, An SK, Joo Y-H, Kim S-H, Yoon DJ, Jho K-H, Koo Y-J, Lee JY: Reliability and validity of the Korean version of the positive and negative syndrome scale. Korean Neuropsychiatric Association. 2002, 40: 1090-1105.","journal-title":"Korean Neuropsychiatric Association"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0195-6663(84)80008-2","volume":"5","author":"AJ Hill","year":"1984","unstructured":"Hill AJ, Magson LD, Blundell JE: Hunger and palatability: tracking ratings of subjective experience before, during and after the consumption of preferred and less preferred food. Appetite. 1984, 5: 361-371. 10.1016\/S0195-6663(84)80008-2.","journal-title":"Appetite"},{"key":"460_CR34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1172\/JCI117807","volume":"95","author":"RL Weinsier","year":"1995","unstructured":"Weinsier RL, Nelson KM, Hensrud DD, Darnell BE, Hunter GR, Schutz Y: Metabolic predictors of obesity. Contribution of resting energy expenditure, thermic effect of food, and fuel utilization to four-year weight gain of post-obese and never-obese women. J Clin Invest. 1995, 95: 980-985. 10.1172\/JCI117807.","journal-title":"J Clin Invest"},{"key":"460_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","volume":"29","author":"R Coccurello","year":"2009","unstructured":"Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, Moles A: 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. J Clin Psychopharmacol. 2009, 29: 576-583. 10.1097\/JCP.0b013e3181bfe13e.","journal-title":"J Clin Psychopharmacol"},{"key":"460_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","volume":"186","author":"R Coccurello","year":"2006","unstructured":"Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A: Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl). 2006, 186: 561-571. 10.1007\/s00213-006-0368-5.","journal-title":"Psychopharmacology (Berl)"},{"key":"460_CR37","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/oby.2010.17","volume":"18","author":"M Liebig","year":"2010","unstructured":"Liebig M, Gossel M, Pratt J, Black M, Haschke G, Elvert R, Juretschke HP, Neumann-Haefelin C, Kramer W, Herling AW: Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring). 2010, 18: 1952-1958. 10.1038\/oby.2010.17.","journal-title":"Obesity (Silver Spring)"},{"issue":"Suppl 2","key":"460_CR38","doi-asserted-by":"publisher","first-page":"173S","DOI":"10.1002\/j.1550-8528.1995.tb00460.x","volume":"3","author":"Y Schutz","year":"1995","unstructured":"Schutz Y: Abnormalities of fuel utilization as predisposing to the development of obesity in humans. Obes Res. 1995, 3 (Suppl 2): 173S-178S.","journal-title":"Obes Res"}],"container-title":["Behavioral and Brain Functions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1744-9081-9-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T09:36:45Z","timestamp":1688377005000},"score":1,"resource":{"primary":{"URL":"https:\/\/behavioralandbrainfunctions.biomedcentral.com\/articles\/10.1186\/1744-9081-9-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/1744-9081-9-27","relation":{},"ISSN":["1744-9081"],"issn-type":[{"value":"1744-9081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,19]]},"assertion":[{"value":"21 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}